According to the World Health Organization (WHO), in December 2019, a series of pneumonia cases of unknown cause emerged in Wuhan, Hubei, China. The cases were later identified to be a novel coronavirus, which was initially named 2019 novel coronavirus (2019-nCoV) and, later on, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).1 The disease caused by the viral infection has been named coronavirus disease (COVID-19).2 On 11 March 2020, the WHO declared the COVID-19 outbreak a pandemic. So far (May 28, 2020) the virus has reached over 200 countries, resulting in nearly 5.5 million confirmed cases and more than 300 000 deaths.3 It is predicted that the disease will reach over 2.4 billion people, with 10.4 million deaths and approximately 2.3 billion recoveries worldwide.4
People infected with SARS-CoV-2 present with respiratory tract infection and influenza-like symptoms such as fever, cough, fatigue, sputum production, dyspnoea, sore throat, and headache.5,6 The virus can cause a spectrum of disease from mild upper respiratory symptoms to severe life-threatening pneumonia. The WHO estimates that 80% of cases are asymptomatic or mild and 20% of cases are severe (with 5% considered critical [i.e. requiring ventilation and life support]).1
Although it is too early to establish the long-term effects of the infection, medium- to long-term damage is expected. Data from studies that investigated the impact of severe acute respiratory syndrome (SARS) on pulmonary function and exercise capacity demonstrated impairment in lung function in up to 23% of patients at 1-year follow up as well as a reduction in exercise capacity when compared to predicted values in a normal population.7,8 Given the intensive medical management for people with severe/critical COVID-19, which can include prolonged mechanical ventilation, sedation, and use of neuromuscular blocking agents, this specific population may be at high risk of developing intensive care unit acquired weakness: a disease that has long-term effects on symptoms and physical function.9 It is therefore essential to provide people with severe/critical COVID-19, following hospital discharge, with follow-up assessments focused on symptoms as well as physical and psychological function, and refer those with important symptoms and/or impairments in physical/psychological function to rehabilitation programs.
Physical therapists are one of the health professionals considered extremely important on the management of people with COVID-19.10 In fact, a group of international experts in cardiorespiratory physical therapy developed a document with clinical recommendations for physical therapy management of COVID-19 in the hospital setting.11 There is also a Task Force being prepared that will describe potential rehabilitation interventions in survivors of COVID-19.12
The benefits of pulmonary rehabilitation are well known and the existing programs could be used as one of the rehabilitation referral pathways for COVID-19 survivors who present with symptoms and/or impairments in physical function. The main component of pulmonary rehabilitation programs is exercise training, which includes aerobic and/or resistance training,13 and these exercises have been demonstrated to decrease the negative effects prolonged sedentary behaviour and inactivity during a hospitalisation period have on physical function.14–16 Pulmonary rehabilitation has also been shown to increase exercise capacity, muscle strength, and health-related quality of life in several populations with respiratory conditions.16–18
The impact that COVID-19 has had on healthcare systems worldwide is unprecedented and, accordingly, most of the healthcare resources allocated to COVID-19 treatment to date have focused on supporting the acute care setting. Policy-makers, health care professionals, and providers need to now start mobilising their resources towards building and/or expanding rehabilitation services, including pulmonary rehabilitation, to provide the best care for survivors of COVID-19, so that these people can return to their “normal” life, work and routine, including daily and leisure activities.
Conflicts of interestThe authors declare no conflicts of interest.